By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NeuroSigma, Inc. 

10960 Wilshire Boulevard
Suite 1230
Los Angeles  California  90024  U.S.A.
Phone: 310-479-3100 Fax: n/a


SEARCH JOBS


Industry
Medical Device






Company News
Preliminary Results Utilizing NeuroSigma's Monarch eTNS System For The Treatment Of Traumatic Brain Injury Presented At The North American Neuromodulation Society Annual Meeting 12/10/2015 6:54:35 AM
NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD 11/16/2015 8:39:38 AM
NeuroSigma Withdraws $50 Million IPO Plans 9/29/2015 6:43:09 AM
FDA Grants Faustus Forschungs Cie. Translational Cancer Resea Humanitarian Use Device (HUD) Designation 1/6/2015 10:52:56 AM
University of California, Los Angeles (UCLA) Launches Phase 2 Pediatric Clinical Trial For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS System 1/5/2015 7:08:58 AM
NeuroSigma, Inc. Congratulates Brazilian Medical Team For Their Top-Line Results In Phase 2 Clinical Trial Of Etns For Treatment Of Depression 11/19/2014 12:03:44 PM
NeuroSigma, Inc. Announces Top-Line Findings Of University of California, Los Angeles (UCLA) Phase 2 Clinical Trial Of eTNS For The Treatment Of Depression 11/17/2014 10:13:00 AM
NeuroSigma, Inc. Receives Notice Of Allowance From The Mexican Institute Of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 11/3/2014 8:21:29 AM
NeuroSigma, Inc. Receives Notice of Allowance Of U.S. Patent Application 10/21/2014 8:10:07 AM
NeuroSigma, Inc. And The U.S. Veterans Administration (VA) Enter Into Cooperative Research And Development Agreement (CRADA) 10/15/2014 8:28:43 AM
12345
//-->